Kura oncology to present updated data from komet-007 combination trial of ziftomenib at ash annual meeting

– ziftomenib combined with 7+3 in 1l npm1-m or kmt2a-r adverse risk aml patients selected for oral presentation on saturday, december 7th –

ASH Ratings Summary

ASH Quant Ranking